Stempoint Capital LP Invests $1.01 Million in Biodesix, Inc. $BDSX

Stempoint Capital LP bought a new position in Biodesix, Inc. (NASDAQ:BDSX) during the first quarter, Holdings Channel.com reports. The fund bought 70,004 shares of the company’s stock, valued at approximately $1,015,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BDSX. XTX Topco Ltd lifted its stake in Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after purchasing an additional 102,494 shares during the last quarter. Cetera Investment Advisers acquired a new position in Biodesix in the fourth quarter worth approximately $68,000. DRW Securities LLC bought a new position in shares of Biodesix in the fourth quarter valued at $105,000. Millennium Management LLC bought a new position in shares of Biodesix in the third quarter valued at $113,000. Finally, State Street Corp lifted its position in shares of Biodesix by 15.6% during the 4th quarter. State Street Corp now owns 17,802 shares of the company’s stock valued at $121,000 after acquiring an additional 2,400 shares during the last quarter. 20.96% of the stock is owned by institutional investors and hedge funds.

Biodesix Stock Down 3.1%

BDSX stock opened at $20.38 on Thursday. Biodesix, Inc. has a 52-week low of $5.26 and a 52-week high of $24.92. The company’s 50 day simple moving average is $18.68 and its 200-day simple moving average is $15.05. The company has a debt-to-equity ratio of 5.09, a current ratio of 2.82 and a quick ratio of 2.82. The firm has a market capitalization of $211.14 million, a P/E ratio of -5.02 and a beta of 0.53.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.32. Biodesix had a negative net margin of 33.26% and a negative return on equity of 2,101.40%. The business had revenue of $25.55 million during the quarter, compared to the consensus estimate of $23.12 million. As a group, equities research analysts anticipate that Biodesix, Inc. will post -2.91 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on BDSX. Weiss Ratings raised Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. Roth Capital initiated coverage on Biodesix in a research report on Wednesday, June 24th. They set a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity Group upped their target price on Biodesix from $22.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Finally, HC Wainwright began coverage on Biodesix in a research report on Monday, June 15th. They issued a “buy” rating and a $26.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Biodesix presently has an average rating of “Moderate Buy” and a consensus price target of $28.33.

Biodesix Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.